Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anakinra
Drug ID BADD_D00141
Description Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001 for the treatment of rheumatoid arthritis.
Indications and Usage For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Marketing Status approved
ATC Code L04AC03
DrugBank ID DB00026
KEGG ID D02934
MeSH ID D053590
PubChem ID Not Available
NDC Product Code 68225-067; 66658-234
Synonyms Interleukin 1 Receptor Antagonist Protein | IL1 Febrile Inhibitor | Febrile Inhibitor, IL1 | IL-1Ra | Urine-Derived IL1 Inhibitor | IL1 Inhibitor, Urine-Derived | Urine Derived IL1 Inhibitor | IL-1 Inhibitor, Urine | IL 1 Inhibitor, Urine | Urine IL-1 Inhibitor | Interleukin 1 Inhibitor, Urine | Antril | Kineret | Anakinra
Chemical Information
Molecular Formula Not Available
CAS Registry Number 143090-92-0
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic reaction10.01.07.001;
Angioedema22.04.02.008;; Available
Cellulitis23.11.02.004; Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Injection site erythema12.07.03.001;; Available
Injection site haemorrhage24.07.01.010;; Available
Injection site inflammation12.07.03.009; Available
Injection site pain12.07.03.011; Available
Injection site reaction12.07.03.015;
Lymphoma16.20.01.001; Available
Neutropenia01.02.03.004--Not Available
Pneumonia22.07.01.003; Available
Rash23.03.13.001--Not Available
Rheumatoid arthritis15.01.03.001; Available
Upper respiratory tract infection22.07.03.011;
White blood cell count decreased13.01.06.012--
Arthritis infective15.01.05.002;
Antibody test positive13.06.03.001--Not Available
The 1th Page    1    Total 1 Pages